Randomized phase II study of cetuximab plus cisplatin/ vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer
- Author
- ROSELL, R1 ; ROBINET, G2 ; PIRKER, R11 ; CHEMAISSANI, A12 ; PEROL, M13 ; RANSON, M. R14 ; ELLIS, P. A15 ; PILZ, K16 ; RECK, M17 ; SZCZESNA, A3 ; RAMLAU, R4 ; CONSTENLA, M5 ; MENNECIER, B. C6 ; PFEIFER, W7 ; O'BYRNE, K. J8 ; WELTE, T9 ; KOLB, R10
[1] Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
[2] Institut de Cancérologie, CHU Morvan, Brest, France
[3] Mazowieckie Centrum Chorob Pluc i Gruzlicy, III Oddzial Chorob Pluc, Otwock, Poland
[4] Wielkopolskie Centrum Chorob Pluc i Gruzlicy, Oddzial Onkologii, Poznan, Poland
[5] Unidad de Oncología, Hospital de Pontevedra, Spain
[6] Service de Pneumologie, Pavilion Laennec, Hôpitaux Universitaires, Strasbourg, France
[7] Abt. f. Atem-u. Lungenkrankheiten, A.6. Krankenhaus d. Stadt Linz, Linz, Austria
[8] Department of Oncology, St James' Hospital, Dublin, Ireland
[9] Abt. Pneumologie, Medizinische Hochschule Hannover, Hannover, Germany
[10] Abteilung f. Lungenkrankheiten, Klinikum Kreuzschwestern Wels, Wels, Austria
[11] Klinische Abteilung für Onkologie, Univ.-Klinik f. Innere Medizin I, Wien, Austria
[12] Lungenklinik Köln-Merheim, Köln, Germany
[13] Service de Pneumologie, Hôpital de la Croix Rousse, Lyon, France
[14] Department of Medical Oncology, Christie Hospital, University of Manchester, Manchester, United Kingdom
[15] Department of Medical Oncology, Guy's Hospital, London, United Kingdom
[16] Medical Sciences Oncology, Clinical Research & Development, Merck Serono, Darmstadt, Germany
[17] Onkologischer Schwerpunkt, Zentrum für Pneumologie und Thoraxchirurgie, Krankenhaus Grosshansdorf, Wohrendamm, Grosshansdorf, Germany - Source
Annals of oncology. 2008, Vol 19, Num 2, pp 362-369, 8 p ; ref : 36 ref
- ISSN
- 0923-7534
- Scientific domain
- Medical oncology; Pharmacology drugs
- Publisher
- Oxford University Press, Oxford
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- NSCLC cetuximab cisplatin epidermal growth factor receptor first-line vinorelbine
- Keyword (fr)
- Anticancéreux Cancer du poumon Carcinome non petite cellule bronchopulmonaire Cisplatine Cétuximab Essai clinique phase II Etude comparative Expression génique Homme Randomisation Récepteur facteur croissance épiderme Récepteur facteur croissance Stade avancé Traitement de première intention Vinorelbine Anti-EGFR Agent alkylant Alcaloïde Anticorps monoclonal Antimitotique Cancer Pathologie de l'appareil respiratoire Pathologie des bronches Pathologie des poumons Platine II Complexe Tumeur maligne
- Keyword (en)
- Antineoplastic agent Lung cancer non-small cell lung carcinoma Cisplatin Cetuximab Phase II trial Comparative study Gene expression Human Randomization Epidermal growth factor receptor Growth factor receptor Advanced stage First line treatment Vinorelbine Alkylating agent Alkaloid Monoclonal antibody Antimitotic Cancer Respiratory disease Bronchus disease Lung disease Platinum II Complexes Malignant tumor
- Keyword (es)
- Anticanceroso Cáncer del pulmón Carcinoma no pequeňa célula bronchopulmonar Cisplatino Cetuximab Ensayo clínico fase II Estudio comparativo Expresión genética Hombre Aleatorización Receptor del factor de crecimiento epidérmico Receptor factor crecimiento Estadio avanzado Tratamiento de primera línea Vinorelbina Agente alquilante Alcaloide Anticuerpo monoclonal Antimitótico Cáncer Aparato respiratorio patología Bronquio patología Pulmón patología Platino II Complejo Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B11 Pneumology / 002B11A Tumors of the respiratory system and mediastinum
- Discipline
- Pharmacological treatments Pulmonology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 20053009
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1093/annonc/mdm474 
https://dx.doi.org/10.1093/annonc/mdm474
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mdm474\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:185:\"Randomized phase II study of cetuximab plus cisplatin\/ vinorelbine compared with cisplatin\/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"362\";s:8:\"\u0000*\u0000epage\";s:3:\"369\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"ROSELL\";s:10:\"\u0000*\u0000aufirst\";s:1:\"R\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:10:\"ROBINET, G\";i:1;s:9:\"PIRKER, R\";i:2;s:14:\"CHEMAISSANI, A\";i:3;s:8:\"PEROL, M\";i:4;s:12:\"RANSON, M. R\";i:5;s:11:\"ELLIS, P. A\";i:6;s:7:\"PILZ, K\";i:7;s:7:\"RECK, M\";i:8;s:11:\"SZCZESNA, A\";i:9;s:9:\"RAMLAU, R\";i:10;s:12:\"CONSTENLA, M\";i:11;s:15:\"MENNECIER, B. C\";i:12;s:10:\"PFEIFER, W\";i:13;s:13:\"O'BYRNE, K. J\";i:14;s:8:\"WELTE, T\";i:15;s:7:\"KOLB, R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:185:\"Randomized phase II study of cetuximab plus cisplatin\/ vinorelbine compared with cisplatin\/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mdm474\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:185:\"Randomized phase II study of cetuximab plus cisplatin\/ vinorelbine compared with cisplatin\/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"362\";s:8:\"\u0000*\u0000epage\";s:3:\"369\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"ROSELL\";s:10:\"\u0000*\u0000aufirst\";s:1:\"R\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:10:\"ROBINET, G\";i:1;s:9:\"PIRKER, R\";i:2;s:14:\"CHEMAISSANI, A\";i:3;s:8:\"PEROL, M\";i:4;s:12:\"RANSON, M. R\";i:5;s:11:\"ELLIS, P. A\";i:6;s:7:\"PILZ, K\";i:7;s:7:\"RECK, M\";i:8;s:11:\"SZCZESNA, A\";i:9;s:9:\"RAMLAU, R\";i:10;s:12:\"CONSTENLA, M\";i:11;s:15:\"MENNECIER, B. C\";i:12;s:10:\"PFEIFER, W\";i:13;s:13:\"O'BYRNE, K. J\";i:14;s:8:\"WELTE, T\";i:15;s:7:\"KOLB, R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:185:\"Randomized phase II study of cetuximab plus cisplatin\/ vinorelbine compared with cisplatin\/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mdm474\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mdm474\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:185:\"Randomized phase II study of cetuximab plus cisplatin\/ vinorelbine compared with cisplatin\/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"362\";s:8:\"\u0000*\u0000epage\";s:3:\"369\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"ROSELL\";s:10:\"\u0000*\u0000aufirst\";s:1:\"R\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:10:\"ROBINET, G\";i:1;s:9:\"PIRKER, R\";i:2;s:14:\"CHEMAISSANI, A\";i:3;s:8:\"PEROL, M\";i:4;s:12:\"RANSON, M. R\";i:5;s:11:\"ELLIS, P. A\";i:6;s:7:\"PILZ, K\";i:7;s:7:\"RECK, M\";i:8;s:11:\"SZCZESNA, A\";i:9;s:9:\"RAMLAU, R\";i:10;s:12:\"CONSTENLA, M\";i:11;s:15:\"MENNECIER, B. C\";i:12;s:10:\"PFEIFER, W\";i:13;s:13:\"O'BYRNE, K. J\";i:14;s:8:\"WELTE, T\";i:15;s:7:\"KOLB, R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:185:\"Randomized phase II study of cetuximab plus cisplatin\/ vinorelbine compared with cisplatin\/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mdm474\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:185:\"Randomized phase II study of cetuximab plus cisplatin\/ vinorelbine compared with cisplatin\/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"362\";s:8:\"\u0000*\u0000epage\";s:3:\"369\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"ROSELL\";s:10:\"\u0000*\u0000aufirst\";s:1:\"R\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:10:\"ROBINET, G\";i:1;s:9:\"PIRKER, R\";i:2;s:14:\"CHEMAISSANI, A\";i:3;s:8:\"PEROL, M\";i:4;s:12:\"RANSON, M. R\";i:5;s:11:\"ELLIS, P. A\";i:6;s:7:\"PILZ, K\";i:7;s:7:\"RECK, M\";i:8;s:11:\"SZCZESNA, A\";i:9;s:9:\"RAMLAU, R\";i:10;s:12:\"CONSTENLA, M\";i:11;s:15:\"MENNECIER, B. C\";i:12;s:10:\"PFEIFER, W\";i:13;s:13:\"O'BYRNE, K. J\";i:14;s:8:\"WELTE, T\";i:15;s:7:\"KOLB, R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:185:\"Randomized phase II study of cetuximab plus cisplatin\/ vinorelbine compared with cisplatin\/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mdm474\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:185:\"Randomized phase II study of cetuximab plus cisplatin\/ vinorelbine compared with cisplatin\/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"362\";s:8:\"\u0000*\u0000epage\";s:3:\"369\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"ROSELL\";s:10:\"\u0000*\u0000aufirst\";s:1:\"R\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:10:\"ROBINET, G\";i:1;s:9:\"PIRKER, R\";i:2;s:14:\"CHEMAISSANI, A\";i:3;s:8:\"PEROL, M\";i:4;s:12:\"RANSON, M. R\";i:5;s:11:\"ELLIS, P. A\";i:6;s:7:\"PILZ, K\";i:7;s:7:\"RECK, M\";i:8;s:11:\"SZCZESNA, A\";i:9;s:9:\"RAMLAU, R\";i:10;s:12:\"CONSTENLA, M\";i:11;s:15:\"MENNECIER, B. C\";i:12;s:10:\"PFEIFER, W\";i:13;s:13:\"O'BYRNE, K. J\";i:14;s:8:\"WELTE, T\";i:15;s:7:\"KOLB, R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:185:\"Randomized phase II study of cetuximab plus cisplatin\/ vinorelbine compared with cisplatin\/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
